Comparison of the efficacy and safety of anti-VEGF monotherapy versus anti-VEGF therapy combined with subthreshold micropulse laser therapy for diabetic macular edema
Comparison of the efficacy and safety of anti-VEGF monotherapy versus anti-VEGF therapy combined with subthreshold micropulse laser therapy for diabetic macular edema
复制标题
DOI：
10.1007/s10103-021-03306-0
复制
发表时间：
2021-04-04
影响因子：
2.1
通讯作者：
Ardagil, Aylin
中科院分区：
文献类型：
--
作者：
Altinel, Meltem Guzin;Acikalin, Banu;Ardagil, Aylin
本研究的目的是比较577 nm阈下微脉冲激光（SML）联合玻璃体内注射贝伐单抗（IVB）与单用IVB治疗糖尿病性黄斑水肿（DME）的疗效和安全性。该回顾性研究包括80例患者的80只眼; 40只眼接受IVB单药治疗，40只眼接受SML-IVB联合治疗。比较两组所需IVB注射的平均次数以及最佳矫正视力（BCVA）和黄斑中心厚度（CMT）值的变化。患者的平均年龄为60.19 ± 7.43岁。两组患者的基线特征相似。在SML-IVB联合组中，所需SML治疗的平均次数为2.1 +/- 0.81。SML-IVB联合治疗组所需IVB注射的平均次数为4.38 +/- 0.81，IVB单药治疗组为5.65 +/- 1.51（p
The purpose of this study is to compare the efficacy and safety of 577-nm subthreshold micropulse laser (SML) and intravitreal bevacizumab injection (IVB) combined therapy with IVB monotherapy in the treatment of diabetic macular edema (DME). This retrospective study included 80 eyes of 80 patients; 40 eyes were treated with IVB monotherapy, and 40 eyes were treated with SML-IVB combined therapy. The mean number of required IVB injections and changes of best corrected visual acuity (BCVA) and central macular thickness (CMT) values were compared between the groups. The mean age of the patients was 60.19 +/- 7.43 years. The baseline characteristics of the patients were similar between the groups. In the SML-IVB combined group, the mean number of required SML sessions was 2.1 +/- 0.81. The mean number of required IVB injections was 4.38 +/- 0.81 in the SML-IVB combined group and 5.65 +/- 1.51 in the IVB monotherapy group (p